secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K/A
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001104659-26-022897
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock widens FY2025 net loss to $377.9M; corrects Q4 EPS to $0.76; BLA resubmission path cleared
--------------------------------------------------------------------------------

- Q4 2025 net loss of $91.0M ($0.76 per share, corrected); FY2025 net loss $377.9M ($3.29 per share), up from $246.3M in 2024.
- No revenue; cash, equivalents, and marketable securities of $367.6M as of Dec 31, 2025.
- Apitegromab BLA resubmission expected in 2026 after FDA constructive meeting with Catalent Indiana; no additional corrective actions.
- New debt facility up to $550M from Blue Owl Capital provides non-dilutive capital; $100M drawn at closing, $100M available Q1 2026, $150M upon FDA approval.
- EMA decision on MAA expected mid-2026; European launch planned H2 2026 starting with Germany.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465926022897/0001104659-26-022897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465926022897/tm267900d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-022897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer